{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:38:28Z","timestamp":1793313508300,"version":"4.5.0"},"reference-count":174,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016297","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:15:50Z","timestamp":1776298550000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-6381","authenticated-orcid":false,"given":"Francesco","family":"Nonino","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology and Statistics; IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Minozzi","sequence":"additional","affiliation":[{"name":"Laboratory of Methodology of Systematic Reviews and Guidelines production, Department of Experimental Oncology; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sambati","sequence":"additional","affiliation":[{"name":"U.O.C. Clinica Neurologica Rete Metropolitana (NeuroMet); IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences for Children and Adults; University of Modena and Reggio Emilia; Modena Italy"},{"name":"Institute of Primary Health Care (BIHAM); University of Bern; Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Baldin","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology and Statistics; IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Bassi","sequence":"additional","affiliation":[{"name":"Medical Library; Azienda USL - IRCCS di Reggio Emilia; Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"De Santis","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology and Statistics; IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marien","family":"Gonzalez-Lorenzo","sequence":"additional","affiliation":[{"name":"Laboratory of Methodology of Systematic Reviews and Guidelines production, Department of Experimental Oncology; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Vignatelli","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology and Statistics; IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[{"name":"Independent Researcher; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edo","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Neurology; Radboud University Medical Centre; Nijmegen Netherlands"},{"name":"Department of Public & Occupational Health; Amsterdam University Medical Centre, University of Amsterdam; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimer's & Dementia"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"020310","DOI":"10.7189\/jogh.09.020310","article-title":"Globalising strategies to meet global challenges: the case of ageing and dementia","volume":"9","author":"Parra","year":"2019","journal-title":"Journal of Global Health"},{"key":"10.1002\/14651858.CD016297-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1474043","DOI":"10.3389\/fmed.2024.1474043","article-title":"Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges","volume":"11","author":"Safiri","year":"2024","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"10284","key":"10.1002\/14651858.CD016297-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer's & Dementia: the Journal of the Alzheimer's Association"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimer's & Dementia"},{"issue":"10","key":"10.1002\/14651858.CD016297-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jamda.2016.06.020","article-title":"Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and meta-analysis","volume":"17","author":"Canevelli","year":"2016","journal-title":"Journal of the American Medical Directors Association"},{"issue":"15","key":"10.1002\/14651858.CD016297-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1212\/WNL.0b013e31826e26b7","article-title":"Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis","volume":"79","author":"Koepsell","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's & Dementia"},{"issue":"19","key":"10.1002\/14651858.CD016297-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.neuron.2023.05.031","article-title":"Tipping points in neurodegeneration","volume":"111","author":"Simons","year":"2023","journal-title":"Neuron"},{"issue":"10452","key":"10.1002\/14651858.CD016297-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiological Reviews"},{"issue":"5054","key":"10.1002\/14651858.CD016297-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD001191.pub4","article-title":"Rivastigmine for alzheimer's disease","volume":"4","author":"Birks","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD016297-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD001190.pub3","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"2018","author":"Birks","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747.pub4","article-title":"Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment","author":"Lim","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub6","article-title":"Memantine for dementia","author":"McShane","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11357-024-01400-z","article-title":"The efficacy of cognitive stimulation, cognitive training, and cognitive rehabilitation for people living with dementia: a systematic review and meta-analysis","volume":"47","author":"Paggetti","year":"2024","journal-title":"GeroScience"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1002\/trc2.70098","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"7618","key":"10.1002\/14651858.CD016297-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.25410","article-title":"Amyloid-b; immunotherapy for Alzheimer disease: is it now a long shot?","volume":"85","author":"Panza","year":"2019","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.14283\/jpad.2022.41","article-title":"Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer's disease","volume":"9","author":"Cohen","year":"2022","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"156","key":"10.1002\/14651858.CD016297-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"Erratum in: BMJ","DOI":"10.1136\/bmj.n156","article-title":"Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis","volume":"372","author":"Ackley","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD016297-BIB0028|cit28","unstructured":"Drug Approval Package: Aduhelm (aducanumab-avwa) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761178Orig1s000TOC.cfm 2021 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761178Orig1s000TOC.cfm"},{"key":"10.1002\/14651858.CD016297-BIB0029|cit29","unstructured":"FDA approves treatment for adults with Alzheimer\u2019s disease https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease 2024 https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease"},{"key":"10.1002\/14651858.CD016297-BIB0030|cit30","unstructured":"FDA converts novel Alzheimer\u2019s disease treatment to traditional approval https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval 2023 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"},{"key":"10.1002\/14651858.CD016297-BIB0031|cit31","unstructured":"Leqembi https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurology"},{"issue":"778","key":"10.1002\/14651858.CD016297-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"r778","DOI":"10.1136\/bmj.r778","article-title":"Concerns about the approval of lecanemab for Alzheimer\u2019s disease","volume":"389","author":"Bakchine","year":"2025","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/alz.13690","article-title":"Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials","volume":"20","author":"Wolters","year":"2024","journal-title":"Alzheimer's & Dementia"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1093\/brain\/awad171","article-title":"Unblinding in the lecanemab trial in Alzheimer\u2019s disease","volume":"146","author":"Van Gool","year":"2023","journal-title":"Brain"},{"key":"10.1002\/14651858.CD016297-BIB0036|cit36","unstructured":"UK Medicines and Healthcare Products Regulatory Agency Lecanemab licensed for adult patients in the early stages of Alzheimer\u2019s disease https:\/\/www.gov.uk\/government\/news\/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease https:\/\/www.gov.uk\/government\/news\/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease"},{"key":"10.1002\/14651858.CD016297-BIB0037|cit37","unstructured":"National Institute for Health and Care Excellence Final draft guidance: Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer\u2019s disease https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11220\/documents https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11220\/documents"},{"key":"10.1002\/14651858.CD016297-BIB0038|cit38","unstructured":"National Institute for Health and Care Excellence Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11221\/documents https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11221\/documents"},{"key":"10.1002\/14651858.CD016297-BIB0039|cit39","unstructured":"Healthcare Institute: new Alzheimer's medication ineffective for reimbursement lecanemab (Leqembi) https:\/\/www.zorginstituutnederland.nl\/actueel\/nieuws\/2026\/02\/18\/zorginstituut-nieuw-alzheimermedicijn-werkt-onvoldoende-voor-vergoeding"},{"key":"10.1002\/14651858.CD016297-BIB0040|cit40","unstructured":"[A25-111] Lecanemab (early Alzheimer\u2019s disease) \u2013 Benefit assessment according to \u00a735a Social Code Book V Available at https:\/\/www.iqwig.de\/en\/projects\/a25-111.html"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1177\/13872877251331640","article-title":"Exploring the efficacy and safety of lecanemab in the management of early Alzheimer\u2019s disease: a systematic review of clinical evidence","volume":"105","author":"Ashmawy","year":"2025","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"10","key":"10.1002\/14651858.CD016297-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/10600280231218253","article-title":"Lecanemab: a humanized monoclonal antibody for the treatment of early Alzheimer disease","volume":"58","author":"Park","year":"2024","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD016297-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/alz.12379","article-title":"Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease","volume":"17","author":"Richard","year":"2021","journal-title":"Alzheimer's & Dementia"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4103\/aian.aian_547_24","article-title":"The efficacy of anti-amyloid monoclonal antibodies in early Alzheimer\u2019s dementia: a systematic review","volume":"28","author":"Mostafa","year":"2025","journal-title":"Annals of Indian Academy of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3233\/JAD-240623","article-title":"Adverse events as a cause of unblinding of allocated arms in anti-amyloid therapy trials: a meta-analysis of the predictive value","volume":"101","author":"Sato","year":"2024","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD016297-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neuroscience.2024.11.029","article-title":"Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer's disease: a systematic review and network meta- analysis","volume":"565","author":"Cao","year":"2025","journal-title":"Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD016297-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s10072-023-07194-w","article-title":"Efficacy of anti-amyloid-\u00df monoclonal antibody therapy in early Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"45","author":"Dantas","year":"2024","journal-title":"Neurological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"afae250","DOI":"10.1093\/ageing\/afae250","article-title":"The Italian guideline on diagnosis and treatment of dementia and mild cognitive impairment","volume":"53","author":"Fabrizi","year":"2024","journal-title":"Age and Ageing"},{"key":"10.1002\/14651858.CD016297-BIB0049|cit49","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016297-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD016297-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD016297-BIB0054|cit54","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) American Psychiatric Association, Arlington, VA. 2000"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.2044-8260.1995.tb01487.x","article-title":"CAMCOG: a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample","volume":"34","author":"Huppert","year":"1995","journal-title":"British Journal of Clinical Psychology"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD016297-BIB0059|cit59","first-page":"266","volume-title":"BINOP: Bulletin de l'Institut National d'\u00c9tude du Travail et d'Orientation Professionnelle","volume":"14","author":"Ray","year":"1958"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016297-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-0-387-79948-3_1791","volume-title":"Encyclopedia of Clinical Neuropsychology","author":"Fish","year":"2011"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer\u2019s disease: the disability assessment for dementia","volume":"53","author":"G\u00e9linas","year":"1999","journal-title":"American Journal of Occupational Therapy"},{"key":"10.1002\/14651858.CD016297-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Galasko","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12877-022-03527-0","article-title":"Psychometric properties of the Alzheimer\u2019s Disease Cooperative Study - Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial","volume":"23","author":"Potashman","year":"2023","journal-title":"BMC Geriatrics"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3233\/jad-160979","article-title":"The mild behavioral impairment checklist (mbi-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations","volume":"56","author":"Ismail","year":"2017","journal-title":"Journal of Alzheimer's Disease"},{"issue":"12","key":"10.1002\/14651858.CD016297-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/jnnp.50.2.183","article-title":"The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician","volume":"50","author":"Levin","year":"1987","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD016297-BIB0069|cit69","unstructured":"World Health Organization WHO International Clinical Trials Registry Platform Available at https:\/\/www.who.int\/tools\/clinical-trials-registry-platform https:\/\/www.who.int\/tools\/clinical-trials-registry-platform"},{"key":"10.1002\/14651858.CD016297-BIB0070|cit70","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016297-BIB0071|cit71","unstructured":"Covidence Veritas Health Innovation 2025"},{"key":"10.1002\/14651858.CD016297-BIB0072|cit72","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD016297-BIB0073|cit73","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016297-BIB0074|cit74","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016297-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch23"},{"key":"10.1002\/14651858.CD016297-BIB0076|cit76","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook 2023"},{"key":"10.1002\/14651858.CD016297-BIB0077|cit77","unstructured":"Review Manager (RevMan) The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD016297-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD016297-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD016297-BIB0080|cit80","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016297-BIB0081|cit81","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016297-BIB0082|cit82","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016297-BIB0083|cit83","unstructured":"Neumann I Assessing the certainty of the evidence about effects Neumann I Sch\u00fcnemann H GRADE Book 1.0 The GRADE Working Group"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.7326\/ANNALS-24-02013","article-title":"GRADE guidance: using thresholds for judgments on health benefits and harms in decision making (GRADE guidance 42)","volume":"178","author":"Wiercioch","year":"2025","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD016297-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016297-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jclinepi.2016.03.018","article-title":"Interpreting GRADE's levels of certainty or quality of the evidence: GRADE for statisticians, considering review information size or less emphasis on imprecision?","volume":"75","author":"Sch\u00fcnemann","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016297-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015.","article-title":"GRADE Working Group. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016297-BIB0088|cit88","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","article-title":"Measurement of health state utilities for economic appraisal","volume":"5","author":"Torrance","year":"1986","journal-title":"Journal of Health Economics"},{"key":"10.1002\/14651858.CD016297-BIB0090|cit90","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2025"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/ebmed-2017-110668","article-title":"Rating the certainty in evidence in the absence of a single estimate of effect","volume":"22","author":"Murad","year":"2017","journal-title":"Evidence Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016297-BIB0093|cit93","unstructured":"Trial Forge PRO EDI interpretation guidance 25\/4\/2024 https:\/\/www.trialforge.org\/trial-diversity\/pro-edi-improving-how-equity-diversity-and-inclusion-is-handled-in-evidence-synthesis\/ 2024"},{"key":"10.1002\/14651858.CD016297-BIB0094|cit94","unstructured":"Trial Forge PRO EDI participant characteristics table 22\/3\/2024 https:\/\/www.trialforge.org\/trial-diversity\/pro-edi-improving-how-equity-diversity-and-inclusion-is-handled-in-evidence-synthesis\/ 2024"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1355819619841647","article-title":"Development of the ACTIVE framework to describe stakeholder involvement in systematic reviews","volume":"24","author":"Pollock","year":"2019","journal-title":"Journal of Health Services Research & Policy"},{"issue":"20","key":"10.1002\/14651858.CD016297-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig Lawrence","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016297-BIB0099|cit99","unstructured":"A phase 3b\/4 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of aducanumab (BIIB037) in participants with Alzheimer's disease https:\/\/clinicaltrials.gov\/study\/NCT05310071"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3233\/JAD-240221","article-title":"Long-term safety of gantenerumab in participants with Alzheimer\u2019s disease: a phase III, double-blind, and open-label extension study (Marguerite RoAD)","volume":"101","author":"Neve","year":"2024","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer's Research & Therapy"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","article-title":"Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients","volume":"12","author":"Siemers","year":"2016","journal-title":"Alzheimer's & Dementia"},{"issue":"6","key":"10.1002\/14651858.CD016297-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimer's Research & Therapy"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD016297-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"11","key":"10.1002\/14651858.CD016297-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD016297-BIB0113|cit113","unstructured":"A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018%E2%80%90004739%E2%80%9058%E2%80%90ES"},{"key":"10.1002\/14651858.CD016297-BIB0114|cit114","unstructured":"Dominantly inherited alzheimer network trial: an opportunity to prevent dementia. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset alzheimer's disease caused by a genetic mutation. Master protocol DIAN-TU-001 https:\/\/clinicaltrials.gov\/study\/NCT01760005"},{"key":"10.1002\/14651858.CD016297-BIB0115|cit115","unstructured":"Global study to investigate safety and efficacy of donanemab in early symptomatic alzheimer's disease https:\/\/www.clinicaltrials.gov\/study\/NCT05508789?utm_source=trialradar"},{"key":"10.1002\/14651858.CD016297-BIB0116|cit116","unstructured":"A study of remternetug versus placebo in early alzheimer's disease participants at risk for cognitive and functional decline https:\/\/clinicaltrials.gov\/study\/NCT06653153"},{"key":"10.1002\/14651858.CD016297-BIB0117|cit117","unstructured":"A double-blind, placebo-controlled, double-dummy study of donanemab and RG6289 in PSEN1 E280A mutation carriers, and in non-randomized, placebo-treated non-carriers from the same kindred, to evaluate the efficacy and safety of donanemab, RG6289, or the combination of donanemab and RG6289, in the treatment of autosomal-dominant alzheimer's disease https:\/\/clinicaltrials.gov\/study\/NCT06996730"},{"key":"10.1002\/14651858.CD016297-BIB0118|cit118","unstructured":"A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) https:\/\/clinicaltrials.gov\/study\/NCT05738486"},{"key":"10.1002\/14651858.CD016297-BIB0119|cit119","unstructured":"Phase I clinical study of crenezumab in patients with alzheimer's disease https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2080223155"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","article-title":"Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited alzheimer disease","volume":"92","author":"Joseph-Mathurin","year":"2022","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer's disease: rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimers & Dementia"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"2","key":"10.1002\/14651858.CD016297-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"7638","key":"10.1002\/14651858.CD016297-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/bmj.39433.616678.25","article-title":"Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up","volume":"336","author":"Xie","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10654-025-01220-1","article-title":"Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer's disease to individuals with mild cognitive impairment or early Alzheimer's disease in the general population","volume":"40","author":"Claus","year":"2025","journal-title":"European Journal of Epidemiology"},{"issue":"19","key":"10.1002\/14651858.CD016297-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD016297-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD016297-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"e1004568","DOI":"10.1371\/journal.pmed.1004568","article-title":"Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: a systematic review and meta-analysis","volume":"22","author":"Tonegawa-Kuji","year":"2025","journal-title":"PLOS Medicine"},{"issue":"9","key":"10.1002\/14651858.CD016297-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/alz.12528","article-title":"Risk of Alzheimer's disease and related dementia by sex and race\/ethnicity: the Multiethnic Cohort Study","volume":"18","author":"Lim","year":"2022","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD016297-BIB0131|cit131","unstructured":"Lucas P Li D Lobello K Liu E Brashear HR Styren S Intravenous bapineuzumab in mild to moderate Alzheimer's disease: Results from two double-blind, placebo-controlled phase 3 trials Journal of Nutrition, Health & Aging 2013 806 7"},{"key":"10.1002\/14651858.CD016297-BIB0132|cit132","unstructured":"Study evaluating the safety and efficacy of bapineuzumab in Alzheimer disease patients or a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of bapineuzumab in subjects with mild to moderate Alz https:\/\/clinicaltrials.gov\/study\/NCT00667810"},{"key":"10.1002\/14651858.CD016297-BIB0133|cit133","unstructured":"A phase iii, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (aab 001, eln115727) in subjects with mild to moderate alzheimer disease who are apolipoprotein e 4 carriers https:\/\/clinicaltrials.gov\/study\/NCT00676143"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3233\/jad-180675","article-title":"Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies","volume":"66","author":"Brashear","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"issue":"8","key":"10.1002\/14651858.CD016297-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"692-700","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016297-BIB0136|cit136","unstructured":"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's disease who are apolipoprotein E4 non- carriers https:\/\/clinicaltrials.gov\/study\/NCT00574132"},{"key":"10.1002\/14651858.CD016297-BIB0137|cit137","unstructured":"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's disease who are apolipoprotein E4 carriers https:\/\/clinicaltrials.gov\/study\/NCT00575055"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","volume":"12","author":"Chen","year":"2025","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1002\/14651858.CD016297-BIB0140|cit140","unstructured":"Sabbagh M Li D Dhadda S Irizarry M Hersch S Giorgi L Aria by clinical subgroup and baseline amyloid PET centiloid levels from the lecanemab clarity ad study Journal of Prevention of Alzheimer's Disease 2023 S91 10.14283\/jpad.2022.130"},{"key":"10.1002\/14651858.CD016297-BIB0141|cit141","doi-asserted-by":"crossref","unstructured":"Sabbagh M Cummings J Van Dyck C Hersch S Kanekiyo M Dhadda S Isolated ARIA-H in patients treated with lecanemab in the phase 3 clarity AD study in early Alzheimer's disease Journal of the Neurological Sciences 2023 10.1016\/j.jns.2023.121401","DOI":"10.1016\/j.jns.2023.121401"},{"key":"10.1002\/14651858.CD016297-BIB0142|cit142","doi-asserted-by":"crossref","unstructured":"Van Dyck CH Randall B Sharon C Rob M Marwan S Michael I Lecanemab clarity ad: results from a randomised, double-blind phase 3 early Alzheimer's disease trial Journal of Neurology, Neurosurgery and Psychiatry 2023 A45 A46 10.1136\/JNNP-2023-ABN.139","DOI":"10.1136\/JNNP-2023-ABN.139"},{"key":"10.1002\/14651858.CD016297-BIB0143|cit143","unstructured":"CREAD study: a study of crenezumab versus placebo to evaluate the efficacy and safety in participants with prodromal to mild Alzheimer's disease (AD) https:\/\/clinicaltrials.gov\/study\/NCT02670083"},{"key":"10.1002\/14651858.CD016297-BIB0144|cit144","unstructured":"A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with prodromal to mild Alzheimer's disease https:\/\/clinicaltrials.gov\/study\/NCT03114657"},{"key":"10.1002\/14651858.CD016297-BIB0145|cit145","unstructured":"Cohen S Cummings J Murphy J He P Levitchi Benea M Forrestal F Progression analysis on cognitive, functional, and behavioral endpoints in emerge, a phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer's disease Journal of Prevention of Alzheimer's Disease 2023 S46 S47 10.14283\/jpad.2022.129"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD016297-BIB0147|cit147","unstructured":"221AD302 phase 3 study of aducanumab in early Alzheimer's disease https:\/\/clinicaltrials.gov\/study\/NCT02484547"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.14283\/jpad.2024.106","article-title":"Japanese subgroup analyses from EMERGE and ENGAGE, phase 3 clinical trials of aducanumab in patients with early Alzheimer's disease","volume":"11","author":"Toda","year":"2024","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD016297-BIB0149|cit149","unstructured":"A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer's disease https:\/\/clinicaltrials.gov\/study\/NCT02477800"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14283\/jpad.2018.1","article-title":"Delayed-start analyses in the phase 3 solanezumab EXPEDITION3 study in mild Alzheimer's disease","volume":"5","author":"Liu-Seifert","year":"2018","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD016297-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.trci.2019.05.007","article-title":"Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease","volume":"5","author":"Schwarz","year":"2019","journal-title":"Alzheimer's & Dementia (New York, NY)"},{"key":"10.1002\/14651858.CD016297-BIB0152|cit152","unstructured":"Effect of passive immunization on the progression of mild Alzheimer's disease: solanezumab (LY2062430) versus placebo https:\/\/clinicaltrials.gov\/study\/NCT01900665"},{"key":"10.1002\/14651858.CD016297-BIB0153|cit153","unstructured":"Effect of passive immunization on the progression of Alzheimer\u2019s disease: solanezumab (LY2062430) versus placebo https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2008-007926-21"},{"key":"10.1002\/14651858.CD016297-BIB0154|cit154","doi-asserted-by":"crossref","unstructured":"Carlson CD Anglin G Case MG Crowe B Marie Hake A Khanna R Safety of solanezumab in phase 3 studies in individuals with mild Alzheimer's disease dementia Alzheimer's & Dementia 2017 P251 P252","DOI":"10.1016\/j.jalz.2017.06.111"},{"key":"10.1002\/14651858.CD016297-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","article-title":"Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease","volume":"2","author":"Carlson","year":"2016","journal-title":"Alzheimer's & Dementia (Amsterdam, Netherlands)"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ncn3.12140","article-title":"Disease-modifying effect of solanezumab evaluated by delayed-start analysis in a Japanese subpopulation with mild Alzheimer's disease","volume":"5","author":"Nakamura","year":"2017","journal-title":"Neurology and Clinical Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016297-BIB0158|cit158","doi-asserted-by":"crossref","unstructured":"Chen YF Ma X Sundell K Alaka K Schuh K Raskin J Use of quantile regression to characterize solanezumab effects across percentiles of disease progression in expedition Alzheimer's disease trials Alzheimer's & Dementia 2014 P448","DOI":"10.1016\/j.jalz.2014.05.608"},{"key":"10.1002\/14651858.CD016297-BIB0159|cit159","unstructured":"Effect of LY2062430, an anti-amyloid beta monoclonal antibody, on the progression of Alzheimer's disease as compared with placebo https:\/\/clinicaltrials.gov\/study\/NCT00905372"},{"issue":"4","key":"10.1002\/14651858.CD016297-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"e70192","DOI":"10.1002\/alz.70192","article-title":"Japanese participant data from three gantenerumab trials in early Alzheimer's disease","volume":"21","author":"Asada","year":"2025","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"19; Erratum in:","DOI":"10.1001\/jamaneurol.2024.3937","article-title":"Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early alzheimer disease","volume":"82","author":"Salloway","year":"2025","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD016297-BIB0162|cit162","unstructured":"Efficacy and safety study of gantenerumab in participants with early Alzheimer's disease (AD) https:\/\/www.clinicaltrials.gov\/study\/NCT03444870"},{"key":"10.1002\/14651858.CD016297-BIB0163|cit163","unstructured":"Safety and efficacy study of gantenerumab in participants with early Alzheimer's disease (AD) https:\/\/clinicaltrials.gov\/study\/NCT03443973"},{"key":"10.1002\/14651858.CD016297-BIB0164|cit164","unstructured":"A study of gantenerumab in patients with mild Alzheimer disease https:\/\/clinicaltrials.gov\/study\/NCT02051608"},{"issue":"1","key":"10.1002\/14651858.CD016297-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-018-0409-4","article-title":"Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"10","author":"Ostrowitzki","year":"2018","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1002\/14651858.CD016297-BIB0166|cit166","doi-asserted-by":"crossref","unstructured":"Lasser R Scheltens P Dubois B Nikolcheva T Retout S Volz D Efficacy, safety and biomarker data from scarlet road-a global phase 3 study of gantenerumab in patients with prodromal ad American Journal of Geriatric Psychiatry 2016 S161 S162","DOI":"10.1016\/j.jagp.2016.02.034"},{"issue":"7","key":"10.1002\/14651858.CD016297-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"P254","DOI":"10.1016\/j.jalz.2017.06.115","article-title":"Relationship between vascular pathologyat baseline and amyloid-related imaging abnormalities (ARIA) in prodromal AD patient population in scarlet road study","volume":"13","author":"Andjelkovic","year":"2017","journal-title":"Alzheimer's & Dementia"},{"issue":"7","key":"10.1002\/14651858.CD016297-BIB0168|cit168","first-page":"P331","article-title":"Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: results from SCarlet RoAD-a global, multicenter trial","volume":"11","author":"Lasser","year":"2015","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD016297-BIB0169|cit169","unstructured":"A study of gantenerumab in participants with prodromal Alzheimer's disease (Scarlet Road) https:\/\/clinicaltrials.gov\/study\/NCT01224106"},{"issue":"5","key":"10.1002\/14651858.CD016297-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurology"},{"issue":"3","key":"10.1002\/14651858.CD016297-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese patients with early Alzheimer's disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurology and Therapy"},{"key":"10.1002\/14651858.CD016297-BIB0172|cit172","unstructured":"Shcherbinin S Lu M Wang J Wang H Hauck P Gueorguieva I Rapid amyloid clearance and efficacy: results from Trailblazer-alz 2, a phase 3 study of donanemab for treatment of early Alzheimer's disease Journal of Prevention of Alzheimer's Disease 2023 S42 S43 10.14283\/jpad.2022.129"},{"key":"10.1002\/14651858.CD016297-BIB0173|cit173","unstructured":"Evans CD Zimmer JA Wessels AM Lu M Sparks J Mintun M Efficacy of donanemab by apoe4 carrier status in trailblazer-alz 2, a phase 3 randomized clinical trial in early symptomatic Alzheimer's disease Journal of Prevention of Alzheimer's Disease 2023 S40 S41 10.14283\/jpad.2022.129"},{"key":"10.1002\/14651858.CD016297-BIB0174|cit174","unstructured":"Assessment of safety, tolerability, and efficacy of donanemab in early symptomatic Alzheimer's disease https:\/\/clinicaltrials.gov\/study\/NCT04437511"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:34:26Z","timestamp":1790739266000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016297"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":174,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016297","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}